Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

312 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.
Patnaik A, Eckhardt SG, Izbicka E, Tolcher AA, Hammond LA, Takimoto CH, Schwartz G, McCreery H, Goetz A, Mori M, Terada K, Gentner L, Rybak ME, Richards H, Zhang S, Rowinsky EK. Patnaik A, et al. Among authors: rowinsky ek. Clin Cancer Res. 2003 Oct 15;9(13):4761-71. Clin Cancer Res. 2003. PMID: 14581347 Clinical Trial.
A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms.
Hammond LA, Eckardt JR, Kuhn JG, Gerson SL, Johnson T, Smith L, Drengler RL, Campbell E, Weiss GR, Von Hoff DD, Rowinsky EK. Hammond LA, et al. Among authors: rowinsky ek. Clin Cancer Res. 2004 Mar 1;10(5):1645-56. doi: 10.1158/1078-0432.ccr-03-0174. Clin Cancer Res. 2004. PMID: 15014015 Clinical Trial.
A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
Tolcher AW, Kuhn J, Schwartz G, Patnaik A, Hammond LA, Thompson I, Fingert H, Bushnell D, Malik S, Kreisberg J, Izbicka E, Smetzer L, Rowinsky EK. Tolcher AW, et al. Among authors: rowinsky ek. Clin Cancer Res. 2004 Aug 1;10(15):5048-57. doi: 10.1158/1078-0432.CCR-03-0701. Clin Cancer Res. 2004. PMID: 15297406 Clinical Trial.
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
Lin CC, Beeram M, Rowinsky EK, Takimoto CH, Ng CM, Geyer CE Jr, Denis LJ, De Bono JS, Hao D, Tolcher AW, Rha SY, Jolivet J, Patnaik A. Lin CC, et al. Among authors: rowinsky ek. Cancer Chemother Pharmacol. 2009 Dec;65(1):167-75. doi: 10.1007/s00280-009-1020-y. Epub 2009 May 16. Cancer Chemother Pharmacol. 2009. PMID: 19449006 Clinical Trial.
Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
de Bono JS, Stephenson J Jr, Baker SD, Hidalgo M, Patnaik A, Hammond LA, Weiss G, Goetz A, Siu L, Simmons C, Jolivet J, Rowinsky EK. de Bono JS, et al. Among authors: rowinsky ek. J Clin Oncol. 2002 Jan 1;20(1):96-109. doi: 10.1200/JCO.2002.20.1.96. J Clin Oncol. 2002. PMID: 11773159 Clinical Trial.
312 results